<?xml version="1.0" encoding="UTF-8"?>
<p>A randomised trial of community‐dwelling older adults between 65 and 82 years old was initiated in 2017/2018 in Hong Kong to evaluate the immunogenicity of eIIVs (
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">http://ClinicalTrials.gov</ext-link> NCT03330132).
 <xref rid="cti21107-bib-0018" ref-type="ref">18</xref> Older adults (Supplementary table 
 <xref rid="cti21107-sup-0002" ref-type="supplementary-material">1</xref>) were randomly allocated to receive the 2017/2018 Northern Hemisphere formulation of either standard FluQuadri (S‐IIV, Sanofi Pasteur, Lyon, France) or one of three eIIVs, including adjuvanted (FluAd, A‐eIIV, Seqirus, Maidenhead, UK), high dose (FluZone high dose, H‐eIIV, Sanofi Pasteur) and recombinant HA (FluBlok, R‐eIIV, Sanofi Pasteur) (Table 
 <xref rid="cti21107-tbl-0001" ref-type="table">1</xref>).
 <xref rid="cti21107-bib-0018" ref-type="ref">18</xref> Sera were collected for baseline responses (day 0) and then after vaccination at days 7 (acute), 30 (short‐term memory) and 365 (long‐term memory) (Figure 
 <xref rid="cti21107-fig-0001" ref-type="fig">1</xref>a). Standard HAI serological responses and T‐cell responses are reported elsewhere.
 <xref rid="cti21107-bib-0018" ref-type="ref">18</xref>
</p>
